C. Blanke

发表

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

J. Fletcher, G. Demetri, H. Joensuu, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies.

B. Druker, M. Heinrich, C. Corless, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.

K. Owzar, M. Bertagnolli, J. Fletcher, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results of the intergroup phase III trial ACOSOG Z9001.

C. Antonescu, G. Demetri, R. Maki, 2010 .

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

A. D. Van den Abbeele, J. Fletcher, G. Demetri, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cost Effectiveness of Imatinib Mesylate in the Treatment of Advanced Gastrointestinal Stromal Tumours

D. Huse, G. Demetri, H. Joensuu, 2007, Clinical drug investigation.

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

A. D. Van den Abbeele, S. Silverman, D. Tuveson, 2002, The New England journal of medicine.

Imatinib pharmacokinetics (PK) and its correlation with clinical response in patients with unresectable/metastatic gastrointestinal stromal tumor (GIST)

G. Demetri, H. Joensuu, C. Blanke, 2008 .

Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518.

Helen X. Chen, C. Moran, James C Yao, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

James Allison, Stephen Forman, Massimo Cristofanilli, 2015, Mayo Clinic proceedings.

SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma

H. Lenz, A. El-Khoueiry, C. Blanke, 2012, Investigational New Drugs.

Phase I Trial of Sorafenib Following Liver Transplantation in Patients with High-Risk Hepatocellular Carcinoma

R. Finn, A. El-Khoueiry, A. Venook, 2015, Liver Cancer.

Combined modality therapy in non‐small cell lung cancer

David H. Johnson, C. Blanke, David H. Johnson, 1995, Current opinion in oncology.

Optimal duration of adjuvant therapy for patients with resected gastrointestinal stromal tumors.

C. Blanke, 2012, JAMA.

Biomarkers in GIST: Partly Ready for Prime-Time Use

C. Blanke, 2009, Clinical Cancer Research.

Prognosis of adenocarcinoma arising in Barrett's esophagus.

S. Hoff, H. Choy, C. Blanke, 1998, The Annals of thoracic surgery.

Dual-antibody therapy in advanced colorectal cancer: gather ye rosebuds while ye may.

C. Blanke, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Expression of β-catenin, α-catenin, and E-cadherin in Barrett's esophagus and esophageal adenocarcinomas

K. Washington, David H. Johnson, Y. Shyr, 1998 .

A pilot study of protracted low dose cisplatin and etoposide with concurrent thoracic radiotherapy in unresectable stage III nonsmall cell lung cancer.

Y. Shyr, C. Blanke, B. Epstein, 1997, International journal of radiation oncology, biology, physics.

Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small-cell lung cancer: a Hoosier Oncology Group protocol.

R. Tokars, C. Blanke, W. Fisher, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor

T. Pajak, A. Godwin, B. Eisenberg, 2009, Molecular Cancer Therapeutics.

Gastrointestinal stromal tumors and the evolution of targeted therapy.

C. Blanke, R. Sanborn, 2005, Clinical advances in hematology & oncology : H&O.

Colorectal Chemoprevention Pilot Study (SWOG-9041), randomized and placebo controlled: the importance of multiple luminal lesions.

D. Alberts, C. Fenoglio-Preiser, C. Blanke, 2011, Clinical colorectal cancer.

Metastatic colorectal cancer: Treatment strategies with current cytotoxic regimens

C. Blanke, 2006 .

Low dose versus high dose imatinib for gastrointestinal stromal tumors

C. Blanke, 2005, Nature Clinical Practice Gastroenterology &Hepatology.

KRAS and colorectal cancer: ethical and pragmatic issues in effecting real-time change in oncology clinical trials and practice.

W. Wood, R. Goldberg, A. Grothey, 2011, The oncologist.

Panitumumab monotherapy compared with cetuximab and irinotecan combination therapy in patients with previously treated KRAS wild-type metastatic colorectal cancer.

H. Kennecke, C. Blanke, W. Cheung, 2013, Current oncology.

Handbook of Advanced Cancer Care: Colorectal cancer

C. Blanke, 2003 .

Nonoperative Management of Primary Colorectal Cancer in Patients With Stage IV Disease

S. Leach, C. Blanke, C. Scoggins, 1999, Annals of Surgical Oncology.

On the design, conduct and lessons learned from Lung-MAP (SWOGS1400): A biomarker-driven master protocol to evaluate biomarker-driventherapies for previously-treated squamous lung cancer

Stacey, L. Schwartz, M. Leblanc, 2021 .

A USA registry of gastrointestinal stromal tumor patients: changes in practice over time and differences between community and academic practices.

C. Blanke, M. von Mehren, P. Pisters, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase 2 study of MK‐2206, an allosteric inhibitor of AKT, as second‐line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005)

A. Hezel, H. Kennecke, C. Blanke, 2015, Cancer.

Outcome following surgical therapy for gastrointestinal stromal tumors

C. Corless, C. Blanke, B. Sheppard, 2006, Journal of Gastrointestinal Surgery.

Oxaliplatin (OXP) plus protracted infusion 5-fluorouracil (PIFU) and external beam radiation (EBRT) prior to surgery (S) for potentially curable esophageal adenocarcinoma (EA): A Southwest Oncology Group (SWOG) phase II trial with molecular correlates (S0356).

H. Lenz, C. Corless, C. Blanke, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Use of computerized tomography (CT) as an early prognostic indicator of response to imatinib mesylate (IM) in patients with gastrointestinal stromal tumors (GIST).

A. D. Van den Abbeele, J. Manola, G. Demetri, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Trial of Neoadjuvant/Adjuvant Imatinib Mesylate (IM) for Advanced Primary and Metastatic/Recurrent Operable Gastrointestinal Stromal Tumor (GIST) – early results of RTOG 0132

G. Demetri, B. Eisenberg, M. Heinrich, 2011 .

Accomplishments in 2008 in the management of gastrointestinal stromal tumors.

J. Blay, C. Blanke, D. Renouf, 2009, Gastrointestinal cancer research : GCR.

SWOG 0514: A phase II study of sorafenib (BAY 43–9006) as single agent in patients (pts) with unresectable or metastatic gallbladder cancer or cholangiocarcinomas

P. Philip, H. Lenz, A. El-Khoueiry, 2007 .

Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence.

C. Antonescu, M. McCarter, G. Demetri, 2012, Journal of the American College of Surgeons.

Expression of beta-catenin, alpha-catenin, and E-cadherin in Barrett's esophagus and esophageal adenocarcinomas.

K. Washington, Y. Shyr, C. Blanke, 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597.

C. Blanke, A. Sandler, K. Miller, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epidemiology of GIST.

B. Eisenberg, C. Blanke, M. Heinrich, 2005, The American journal of gastroenterology.

NCCN Task Force report: optimal management of patients with gastrointestinal stromal tumor (GIST)--expansion and update of NCCN clinical practice guidelines.

A. D. Van den Abbeele, G. Demetri, B. Eisenberg, 2004, Journal of the National Comprehensive Cancer Network : JNCCN.

SWOG S0809: A phase II trial of adjuvant capecitabine (cap)/gemcitabine (gem) followed by concurrent capecitabine and radiotherapy in extrahepatic cholangiocarcinoma (EHCC) and gallbladder carcinoma (GBCA).

Charles R. Thomas, L. Dawson, M. Thomas, 2014 .

Late recurrence of seminoma.

G. R. Nichols, C. Blanke, S. C. Delgalvis, 1997, Southern medical journal.

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.

L. Saltz, C. Blanke, M. Moore, 2000, The New England journal of medicine.

Postchemotherapy Hyperammonemic Encephalopathy Emulating Ornithine Transcarbamoylase (OTC) Deficiency

C. Blanke, C. Harding, J. Chan, 2008, Southern medical journal.

Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib

G. Demetri, H. Joensuu, M. Heinrich, 2004 .

Gastrointestinal stromal tumors: disease and treatment update.

C. Blanke, M. Ho, 2011, Gastroenterology.

Gastrointestinal stromal tumors: Imatinib and beyond

C. Blanke, I. Schnadig, 2006, Current treatment options in oncology.

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

C. Antonescu, M. McCarter, K. Owzar, 2009, The Lancet.

Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial

P. Philip, C. Blanke, M. Tejani, 2017, JAMA oncology.

Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors.

G. Demetri, A. Racine, H. Joensuu, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.

C. Fenoglio-Preiser, C. Blanke, J. Abbruzzese, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.

J. Ajani, D. Haller, C. Blanke, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Acute tumor lysis syndrome with choriocarcinoma.

C. Blanke, M. Hemmer, R. Witte, 2000, Southern medical journal.

Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665

G. Demetri, B. Eisenberg, M. Heinrich, 2009, Journal of surgical oncology.

Dual blockade of epidermal growth factor receptor and insulin‐like growth factor receptor–1 signaling in metastatic pancreatic cancer: Phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727)

P. Philip, H. Lenz, C. Blanke, 2014, Cancer.

Targeted therapies in the treatment of colorectal cancer: what managed care needs to know.

C. Blanke, R. Schwartz, L. Pesko, 2004, Journal of managed care pharmacy : JMCP.

Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)

C. Blanke, C. Rankin, J. Abbruzzese, 2009, Investigational New Drugs.

Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205.

A. Khorana, P. Philip, C. Fenoglio-Preiser, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of depsipeptide (NSC-630176) in colorectal cancer patients who have received either one or two prior chemotherapy regimens for metastatic or locally advanced, unresectable disease: A Southwest Oncology Group study.

C. Blanke, P. Hoff, W. G. Harker, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.

A. D. Van den Abbeele, J. Blay, D. Ettinger, 2007, Journal of the National Comprehensive Cancer Network : JNCCN.

SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma.

Charles R. Thomas, L. Dawson, M. Thomas, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors

D. Huse, C. Blanke, 2010, Journal of medical economics.

Protocol for the examination of specimens from patients with gastrointestinal stromal tumor.

M. Washington, J. Goldblum, G. Demetri, 2010, Archives of pathology & laboratory medicine.

Review article Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors

D. Huse, C. Blanke, 2010 .

Metastatic gastrointestinal stromal tumors

C. Blanke, F. Aubin, 2010, Cancer Chemotherapy and Pharmacology.

Successes and Challenges in Translational Research: The Development of Targeted Therapy for Gastrointestinal Stromal Tumours

C. Blanke, D. Renouf, L. Wilson, 2009, Clinical Cancer Research.

Successes and Challenges inTranslational Research : The Development ofTargetedTherapy for Gastrointestinal

C. Blanke, D. Renouf, LoraWilson, 2009 .

JNCCN NCCN Task Force Report : Optimal Management of Patients with Gastrointestinal Stromal Tumor ( GIST ) — Update of the NCCN Clinical Practice Guidelines

J. Blay, D. Ettinger, G. Demetri, 2007 .

CODE (cisplatin, vincristine, doxorubicin, etoposide) plus granulocyte colony-stimulating factor in advanced non-small-cell lung cancer: a Hoosier Oncology Group phase II trial.

L. Einhorn, C. Blanke, A. Sandler, 1998, American journal of clinical oncology.

Kinase M utations a nd I matinib R esponse i n P atients W ith Metastatic G astrointestinal S tromal T umor

J. Fletcher, G. Demetri, S. Singer, 2003 .

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

A. D. Van den Abbeele, J. Fletcher, G. Demetri, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial.

Y. Shyr, C. Blanke, B. Murphy, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Benefits, issues, and recommendations for personalized medicine in oncology in Canada.

M. Sawyer, G. Batist, C. Blanke, 2013, Current oncology.

Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)

R. Kurzrock, C. Blanke, S. Nair, 2021, Journal for ImmunoTherapy of Cancer.

Integration of Antiangiogenic Strategies Into Colorectal Cancer Treatment

C. Blanke, J. Strother, 2007 .

Epithelioid gastric stromal tumours of the antrum in young females with the Carney triad: a report of three new cases with mutational analysis and comparative genomic hybridization.

A. Hartmann, M. Heinrich, C. Corless, 2007, Oncology reports.

Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033

J. Crowley, K. Owzar, J. Fletcher, 2017, JAMA oncology.

Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.

C. Antonescu, M. McCarter, K. Owzar, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Management of gastrointestinal stromal tumors in the imatinib era: selected case studies.

J. Blay, S. Bonvalot, B. Eisenberg, 2006, The oncologist.

Commentary (Blanke)—Imatinib Mesylate: A Molecularly Targeted Therapy for Gastrointestinal Stromal Tumors

C. Blanke, Facp., 2003 .

Gastrointestinal stromal tumors

B. Eisenberg, M. Heinrich, C. Blanke, 2001, Current treatment options in oncology.

Follow-up results after 9 years (yrs) of the ongoing, phase II B2222 trial of imatinib mesylate (IM) in patients (pts) with metastatic or unresectable KIT+ gastrointestinal stromal tumors (GIST).

G. Demetri, H. Joensuu, M. Heinrich, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

S9511: A Southwest Oncology Group Phase II Study of Trimetrexate, 5-Fluorouracil, and Leucovorin in Unresectable or Metastatic Adenocarcinoma of the Stomach

B. Issell, K. Chansky, C. Blanke, 2009, American journal of clinical oncology.

SWOG S0518: Phase III prospective randomized comparison of depot octreotide plus interferon alpha-2b versus depot octreotide plus bevacizumab (NSC #704865) in advanced, poor prognosis carcinoid patients (NCT00569127).

Helen X. Chen, C. Moran, C. Blanke, 2015 .

American Society of Clinical Oncology Statement: Human Papillomavirus Vaccination for Cancer Prevention.

L. Foxhall, N. Dupont, C. Blanke, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pain and emotional well-being outcomes in Southwest Oncology Group-directed intergroup trial S0205: a phase III study comparing gemcitabine plus cetuximab versus gemcitabine as first-line therapy in patients with advanced pancreas cancer.

S. Lippman, P. Philip, C. Moinpour, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Transcatheter arterial chemoembolization as primary treatment for hepatocellular carcinoma.

W. Chapman, J. Debelak, C. Pinson, 1999, American journal of surgery.

Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials.

David M. Thomas, D. Sargent, A. Bleyer, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Commentary: clinical trials represent the best cancer care. Or do they?

C. Blanke, Charles D Blanke, 2011, Journal of oncology practice.

Phase II Trial of Neoadjuvant/adjuvant Imatinib Mesylate for Advanced Primary and Metastatic/recurrent Operable Gastrointestinal Stromal Tumors: Long-term Follow-up Results of Radiation Therapy Oncology Group 0132

G. Demetri, Q. Zhang, B. Eisenberg, 2012, Annals of Surgical Oncology.

Cetuximab as Second-Line Therapy in Patients with Metastatic Esophageal Adenocarcinoma: A Phase II Southwest Oncology Group Study (S0415)

H. Lenz, C. Blanke, Wu Zhang, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Paclitaxel, UFT, and calcium folinate in metastatic breast cancer.

C. Blanke, K. Hande, N. Dickson, 1999, Oncology.

Duration of Adjuvant Therapy for Patients With Gastrointestinal Stromal Tumors: Where Is Goldilocks When We Need Her?

R. DeMatteo, C. Blanke, 2016, JAMA Oncology.

Clinical Practice Guidelines for Hepatocellular Carcinoma Differ between Japan, United States, and Europe

T. Murakami, M. Kudo, Y. Minami, 2015, Liver Cancer.

Neoplasms of the Small and Large Intestine

D. Faigel, C. Blanke, 2011 .

NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instabili

N. Wolmark, P. Ganz, S. Kopetz, 2021, Journal of Clinical Oncology.

Dose effect of imatinib (IM) in patients (pts) with metastatic GIST - Phase III Sarcoma Group Study S0033.

J. Crowley, G. Demetri, C. Blanke, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of M1a and M1b category in metastatic colorectal cancer.

H. Kennecke, C. Blanke, S. Gill, 2014, The oncologist.

Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma

C. Blanke, J. Picus, E. Rowinsky, 2000, Cancer.

Hepatocellular carcinoma outcomes based on indicated treatment strategy.

W. Chapman, J. Debelak, C. Pinson, 1998, The American surgeon.

Phase II study of calcitriol-enhanced docetaxel in patients with previously untreated metastatic or locally advanced pancreatic cancer

M. Mori, C. Blanke, T. Beer, 2009, Investigational New Drugs.

Long-term disease control of advanced gastrointestinal stromal tumors (GIST) with imatinib (IM): 10-year outcomes from SWOG phase III intergroup trial S0033.

K. Owzar, J. Fletcher, G. Demetri, 2014 .

Long-term follow-up of a phase II randomized trial in advanced gastrointestinal stromal tumor (GIST) patients (pts) treated with imatinib mesylate.

J. Fletcher, G. Demetri, H. Joensuu, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

KIT as a Therapeutic Target

B. Druker, M. Heinrich, C. Corless, 2003 .

Perioperative treatment of gastrointestinal stromal tumors.

C. Blanke, P. Hoff, G. Fernandes, 2009, Oncology.

Gastrointestinal stromal tumours: three perspectives on current diagnosis and therapy

C. Blanke, 2006 .

Impact of the year 2000 Medicare policy change on older patient enrollment to cancer clinical trials.

J. Crowley, C. Coltman, S. Martino, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors

Helen X. Chen, Preet Paul Singh, R. Kurzrock, 2020, Clinical Cancer Research.

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

J. Crowley, G. Demetri, R. Maki, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer

H. Lenz, W. Zhang, C. Fenoglio-Preiser, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I trial of sorafenib following liver transplantation in patients with high-risk hepatocellular carcinoma.

R. Finn, A. El-Khoueiry, A. Venook, 2015 .

Higher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030)

C. Gotay, H. Lenz, A. Shields, 2013, British Journal of Cancer.

Survival for metastatic colorectal cancer in the bevacizumab era: a population-based analysis.

H. Kennecke, C. Blanke, S. Gill, 2011, Clinical colorectal cancer.

A phase II trial of VP-16, ifosfamide, cisplatin, vinblastine, and bleomycin in advanced germ-cell tumors.

L. Einhorn, C. Blanke, P. Loehrer, 1996, American Journal of Clinical Oncology.

A phase I/II trial of the oral PKC-inhibitor PKC412 (PKC) in combination with imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM

M. Heinrich, C. Blanke, S. Dimitrijević, 2005 .

Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib.

G. Demetri, H. Joensuu, M. Heinrich, 2004, Blood.

Erratum to: Phase II Trial of Neoadjuvant/adjuvant Imatinib Mesylate for Advanced Primary and Metastatic/recurrent Operable Gastrointestinal Stromal Tumors: Long-term Follow-up Results of Radiation Therapy Oncology Group 0132

G. Demetri, Q. Zhang, B. Eisenberg, 2012, Annals of Surgical Oncology.

Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies.

B. Druker, M. Heinrich, C. Corless, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeted therapies in the treatment of colorectal cancer: what managed care needs to know.

C. Blanke, R. Schwartz, L. Pesko, 2004, Journal of managed care pharmacy : JMCP.

Optimal Adjuvant Therapy for Patients with Resected Rectal Cancers

C. Blanke, F. Aubin, 2010 .

Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518.

Helen X. Chen, C. Moran, C. Blanke, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of imatinib mesylate (IM) in patients with large volume gastrointestinal stromal tumors (GISTs)

J. Fletcher, H. Joensuu, B. Eisenberg, 2007 .

Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial.

H. Lenz, C. Blanke, J. Baranda, 2012 .

S9511: A Southwest Oncology Group Phase II Study of Trimetrexate, 5-Fluorouracil, and Leucovorin in Unresectable or Metastatic Adenocarcinoma of the Stomach

B. Issell, K. Chansky, C. Blanke, 2009, American journal of clinical oncology.

Biomarkers in GIST: Partly Ready for Prime-Time Use

C. Blanke, 2009, Clinical Cancer Research.